**Supplementary** **Table 1:** Comparison of baseline information and treatment response between t(11;14) positive and negative group.

|  |  |  |  |
| --- | --- | --- | --- |
| **Factors** | **T(11;14)**  **(*n* = 109)** | **Non-t(11;14)**  **(*n* = 109)** | ***P-*value** |
| Male (%) | 75 (68.8%) | 68 (62.4%) | 0.331 |
| Age (years) (median ± SD) | 59.4 ± 9 | 60.9 ± 10 | 0.247 |
| Free light chain M type | 37 (33.9%) | 22 (20.2%) | 0.019 |
| ISS stage |  |  | 0.181 |
| I | 25 (22.9%) | 15 (13.8%) |  |
| II | 44 (40.4%) | 45 (41.3%) |  |
| III | 40 (36.7%) | 49 (45.0%) |  |
| Renal insufficiency (SCr > 2 mg/dL) | 20 (18.3%) | 24 (22.0%) | 0.500 |
| EMD | 14 (12.8%) | 17 (15.6%) | 0.561 |
| Low PLT(<100×10^9/L) | 19 (17.4%) | 22 (20.2%) | 0.603 |
| High LDH | 12 (11.0%) | 19 (17.4%) | 0.231 |
| PC (%) (median ± SD) | 42.1% ± 25.5% | 42.3% ± 23.9% | 0.949 |
| LMR (median, IQR) | 4.22 (3.36) | 4.22 (3.90) | 0.784 |
| NLR (median, IQR) | 2.49 (3.00) | 2.51 (2.50) | 0.882 |
| Karyotype |  |  |  |
| Hypoploidy | 9/86 (10.5%) | 4/96 (4.2%) | 0.100 |
| Hyperploidy | 10/86 (11.6%) | 11/96 (11.5%) | 0.971 |
| FISH aberration |  |  |  |
| Del (17p) | 8 (7.3%) | 12 (11.0%) | 0.395 |
| Gain/Amp of 1q21 | 50 (45.9%) | 66 (60.6%) | 0.026 |
| CD20 positive | 33/104 (31.7%) | 14/101 (13.9%) | 0.002 |
| Treatment |  |  | 0.130 |
| PI based | 67 (61.5%) | 78 (71.6%) |  |
| IMiDs based | 16 (14.7%) | 15 (13.8%) |  |
| PI + IMiDs | 25 (22.9%) | 13 (11.9%) |  |
| Upfront ASCT | 24 (22.0%) | 21 (19.3%) | 0.616 |
| Response |  |  |  |
| ORR | 85/106 (80.2%) | 81/98 (82.7%) | 0.651 |
| ≥VGPR | 56/106 (52.8%) | 59/98 (60.2%) | 0.289 |
| CR | 24/106 (22.6%) | 31/98 (31.6%) | 0.159 |

Amp: Amplification; ASCT: Autologous Stem Cell Transplantation; CR: Complete response; Del: Deletion; EMD: Extramedullary disease; FISH: Fluorescence in situ hybridization; IMiDs: Immunomodulator; ISS: International staging system; IQR: Interquartile range; LDH: Lactate dehydrogenase; LMR: Lymphocyte monocyte ratio; NLR: Neutrophil lymphocyte ratio; ORR: Overall response; PC: Plasma cell; PLT: Platelet; PI: Proteosome inhibitor; SCr: Serum creatinine; SD: Standard deviation; VGPR: Very good partial response.

**Supplementary Table 2: Comparison of baseline information and treatment response between Gain/Amp of 1q21 positive and negative group.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Factors** | **Gain/Amp of 1q21 positive**  **(*n* = 50)** | **Gain/Amp of 1q21 negative**  **(*n* = 59)** | ***P-*value** |
| Male (%) | 36 (72.0%) | 40 (67.8%) | 0.634 |
| Age (years)(median ± SD) | 60.1 ± 8.5 | 59.4 ± 9.6 | 0.665 |
| Free light chain M protein type | 16 (32%) | 21 (35.6%) | 0.693 |
| ISS stage |  |  | 0.651 |
| I | 13 (26.0%) | 12 (20.3%) |  |
| II | 18 (36.0%) | 26 (44.1%) |  |
| III | 19 (38.0%) | 21 (35.6%) |  |
| Renal insufficiency (SCr > 2 mg/dL) | 10 (20.0%) | 10 (16.9%) | 0.682 |
| EMD | 7 (14.0%) | 6 (11.9%) | 0.740 |
| LMR (median, IQR) | 3.48 (3.23) | 4.61 (4.26) | 0.022 |
| NLR (median, IQR) | 3.14 (3.26) | 2.14 (1.59) | 0.002 |
| Low PLT(<100\*10^9/L) | 8 (16.0%) | 11 (18.6%) | 0.717 |
| High LDH | 6 (12.5%) | 6 (10.2%) | 0.704 |
| PC (%, median ± SD) | 42% ± 27% | 41% ± 24% | 0.552 |
| CD20 | 12/49 (24.5) | 21/55 (38.2) | 0.134 |
| Karyotype |  |  | 0.325 |
| Hypoploidy | 3/44 (6.8%) | 8/56 (14.3%) |  |
| Hyperploidy | 7/44 (15.9%) | 5/56 (8.9%) |  |
| FISH aberration |  |  |  |
| Del (17p) | 3 (6.0%) | 5 (8.5%) | 0.622 |
| Induction treatment |  |  | 0.488 |
| PI based | 30 (60.0%) | 36 (61.0%) |  |
| IMiDs based | 9 (18%) | 7 (11.9%) |  |
| PI + IMiDs | 11 (22.0%) | 14 (23.7%) |  |
| Upfront ASCT | 12 (24.0%) | 12 (20.3%) | 0.646 |
| Response |  |  |  |
| ORR | 38/49 (77.6%) | 47/57 (82.5%) | 0.528 |
| ≥VGPR | 24/49 (49.0%) | 32/57 (56.1%) | 0.462 |
| CR | 10/49 (20.4%) | 14/57 (24.6%) | 0.610 |

Amp: amplification; ASCT: Autologous Stem Cell Transplantation; CR: Complete response; Del: Deletion; EMD: Extramedullary disease; FISH: Fluorescence in situ hybridization; IMiDs: Immunomodulator; ISS: International staging system; IQR: Interquartile range; LDH: Lactate dehydrogenase; LMR: Lymphocyte monocyte ratio; NLR: Neutrophil lymphocyte ratio; ORR: Overall response; PC: Plasma cell; PLT: Platelet; PI: Proteosome inhibitor; SCr: Serum creatinine; SD: Standard deviation; VGPR: Very good partial response.

**Supplementary Table 3: Prognostic factors for PFS and OS in t(11;14) MM.**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Factors** | **PFS** | | | | | | **OS** | | | | | |
| **Univariate** | | | **Multivariate** | | | **Univariate** | | | **Multivariate** | | |
| ***P-*value** | **HR** | **95% CI** | ***P-*value** | **HR** | **95% CI** | ***P-*value** | **HR** | **95% CI** | ***P-*value** | **HR** | **95% CI** |
| Sex | 0.921 |  |  |  |  |  | 0.389 |  |  |  |  |  |
| Age ≥65 | 0.357 |  |  |  |  |  | 0.328 |  |  |  |  |  |
| ISS stage 1/2–3 | 0.040 | 0.939 | 0.884–0.997 | 0.269 |  |  | 0.074 | 0.920 | 0.839–1.008 | 0.913 |  |  |
| Renal insufficiency | 0.002 | 2.528 | 1.387–4.610 | 0.317 |  |  | 0.032 | 2.516 | 1.081–5.858 | 0.505 |  |  |
| EMD | 0.4512 |  |  |  |  |  | 0.522 |  |  |  |  |  |
| High LMR | 0.399 |  |  |  |  |  | 0.064 | 0.453 | 0.196–1.047 | 0.025 | 0.264 | 0.082–0.845 |
| High NLR | 0.809 |  |  |  |  |  | 0.864 |  |  |  |  |  |
| Low PLT | 0.972 |  |  |  |  |  | 0.298 |  |  |  |  |  |
| High LDH | 0.497 |  |  |  |  |  | 0.487 |  |  |  |  |  |
| CD20 | 0.701 |  |  |  |  |  |  |  |  |  |  |  |
| Gain/Amp of 1q21 | 0.005 | 2.158 | 1.259–3.697 | 0.03 | 2.350 | 1.343–4.112 | 0.097 | 2.000 | 0.881–4.542 | 0.004 | 5.660 | 1.725–18.575 |
| Del 17p | 0.591 |  |  |  |  |  | 0.030 | 3.338 | 1.121–9.940 | 0.030 | 4.371 | 1.150–16.607 |
| G-banding | 0.114 |  |  |  |  |  | 0.040 | 0.574 | 0.339–0.974 | 0.209 |  |  |

Amp: Amplification; Del: Deletion; EMD: Extramedullary disease; HR: Hazard ratio; ISS: International staging system; LDH: Lactate dehydrogenase; LMR: Lymphocyte monocyte ratio; MM: Multiple myeloma; NLR: Neutrophil lymphocyte ratio; OS: Overall survival; PLT: Platelet; PFS: Progression free survival.